Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04931654 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
A Phase 1 study of Gastric Cancer and Carcinoma, Non-Small Cell Lung, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 1
- Development phase
- 136
- Enrollment target
- 20
- Study locations
NCT04931654: Active Phase 1 study of Gastric Cancer and Carcinoma, Non-Small Cell Lung, sponsored by AstraZeneca.
NCT04931654 is a Phase 1 study of Gastric Cancer and Carcinoma, Non-Small Cell Lung that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 136 participants, below the 318-participant average among 153 other Gastric Cancer trials with a reported enrollment target (57% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04931654, a Phase 1 study of Gastric Cancer and Carcinoma, Non-Small Cell Lung, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 136 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase I/IIa study designed to evaluate if experimental anti-PD-1 and anti-TIM-3 bispecific antibody, AZD7789 is safe, tolerable and efficacious in participants with advanced solid tumors.
Primary Outcome
Number of participants with AEs, SAEs, imAEs including AEs leading to discontinuation of study intervention and clinically significant alterations in vital signs, laboratory parameters and ECG results
Conditions Studied
Interventions
- DRUG AZD7789
Study Locations (20)
Other
- Research Site - Beijing
- Research Site - Guangzhou
- Research Site - Bordeaux
- Research Site - Rennes
- Research Site - Villejuif
- Research Site - Tbilisi
- Research Site - Chūōku
- Research Site - Kashiwa
- Research Site - Chisinau
- Research Site - Amsterdam
- Research Site - Barcelona
- Research Site - Madrid
- Research Site - Ankara
- Research Site - Ankara
- Research Site - Ankara
Georgia
- Research Site - Atlanta
Indiana
- Research Site - Fort Wayne
New York
- Research Site - New York
Tennessee
- Research Site - Nashville
Ontario
- Research Site - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2021-09-28 |
| Est. Completion | 2026-08-12 |
| Phase | Phase 1 |
What the registry record for NCT04931654 still lists
NCT04931654 is an interventional study that assigns participants to a tested intervention. The registered 136 participants enrollment target is mid-sized for trials with a published cap, below the 318-participant average among 153 other Gastric Cancer trials with a reported enrollment target (57% lower).
The record links to 3 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 1 intervention - of which AZD7789 is the first listed.
NCT04931654 names 20 study sites across 6 states, led by Other, Georgia, Indiana.
Frequently Asked Questions
What is clinical trial NCT04931654 about?
NCT04931654 is a clinical study titled "A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer". This is a Phase I/IIa study designed to evaluate if experimental anti-PD-1 and anti-TIM-3 bispecific antibody, AZD7789 is safe, tolerable and efficacious in participants with advanced solid tumors.
What is the current status of trial NCT04931654?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 136 participants. The study started on 2021-09-28. Estimated completion is 2026-08-12.
What conditions does trial NCT04931654 study?
This clinical trial studies the following conditions: Gastric Cancer, Carcinoma, Non-Small Cell Lung, Gastroesophageal-junction Cancer.
What interventions are being tested in trial NCT04931654?
The interventions under investigation include: AZD7789 (DRUG).
Who is sponsoring clinical trial NCT04931654?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04931654 being conducted?
This trial has 20 study locations across Georgia, Indiana, New York, Tennessee, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04931654's enrollment target sits among peer trials
136 67th of 153 higher than 87 of 153 other Gastric Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gastric Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
A Beta-only IL-2 ImmunoTherapY Study
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01555892 · 136 participants · Phase 1
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
- NCT03216525 · 136 participants · Phase 3
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
- NCT04476901 · 136 participants · Phase 2
Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy
- NCT04603898 · 136 participants · NA
Oxalate Formation From Ascorbic Acid
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI